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Complications that arise from impaired fracture healing have considerable socioeconomic 
implications. Current research in the field of bone tissue engineering predominantly aims 
to mimic the mature bone tissue microenvironment. This approach, however, may 
produce implants that are intrinsically unresponsive to the cues present during the 
initiation of fracture repair. As such, this study describes the development of decellularised 
xenogeneic hyaline cartilage matrix in an attempt to mimic the initial reparative phase of 
fracture repair. Three approaches based on vacuum-assisted osmotic shock (Vac-OS), 
Triton X (Vac-Stx) and SDS (Vac-SDS) were investigated. The Vac-OS methodology reduced 
DNA content below 50ng/mg of tissue, whilst retaining 85% of the sGAG content and as 
such was selected as the optimal methodology for decellularisation.  The resultant Vac-OS 
scaffolds (dcECM) were also devoid of the immunogenic alpha-gal epitope. Furthermore, 
minimal disruption to the structural integrity of the dcECM was demonstrated using 
differential scanning calorimetry (DSC) and fluorescence lifetime imaging microscopy 
(FLIM). The biological integrity of the dcECM was confirmed by its ability to drive the 
chondrogenic commitment and differentiation of human chondrocytes and periosteum-
derived cells respectively. Furthermore, histological examination of dcECM constructs 
implanted in immunocompetent mice revealed a predominantly M2-macrophage driven 
regenerative response both at 2 and 8 weeks post-implantation. These findings contrasted 
with the implanted native costal cartilage that elicited a predominantly M1-macrophage 
mediated inflammatory response. This study highlights the capacity of dcECM from the 
Vac-OS methodology to direct the key biological processes of endochondral ossification, 










































































































































































































Bone tissue has a remarkable capacity for regeneration, driven by mechanisms that govern 
embryonic bone development [1]. Despite this, both internal and external pathological 
factors can hinder the fracture healing process, resulting in delayed or non-union fractures 
[2,3]. 
Autologous bone grafting (ABG) remains the current gold standard treatment approach 
but is hindered by major limitations such as tissue availability and donor site morbidity [4–
6]. Tissue engineering strategies have attempted to produce alternatives, primarily 
through mimicking the desirable properties of ABG [7,8]. These approaches, however, 
mainly aim to mimic mature bone tissue and are therefore intrinsically unresponsive to the 
important biological cues present during early fracture repair. This has led to the 
investigation of endochondral ossification [9], which predominates during embryonic bone 
formation and is also a key driver of long bone fracture repair postnatally [2,3]. The 
cartilaginous callus formed during endochondral fracture repair produces factors that are 
known to promote angiogenesis and calcification, subsequently promoting matrix 
remodelling [10–12]. It has therefore been proposed that recapitulating endochondral 
ossification, or at least the tissue intermediates involved in this process, may facilitate 
bone healing more effectively [13–16].  
Although there have been major advances in the fabrication of synthetic biomaterials, 
their limited ability to be remodelled during the complex process of tissue formation 
results in limited integration[17–21]. Therefore, the use of naturally derived ECM 
constructs is highly appealing as they should be susceptible to tissue remodelling 
processes. Indeed, much research has been associated with the use of decellularised 
tissues from other species to create biological scaffolds.  Decellularised biological scaffolds 
not only retain the original 3D morphological architecture of the tissue but, with 
appropriate attention to production processes, can also retain a complex mixture of 
proteins and macromolecules that aid the proliferation and differentiation of endogenous 
or exogenous cells. Importantly, the structural and functional proteins of the ECM are 








































































































































































































be implanted in recipients of different species without an immune reaction [22]. The 
avoidance of tissue rejection in the recipient has catapulted the use of decellularised 
scaffolds to the forefront of regenerative medicine and tissue engineering, as evidenced by 
the success of human tracheal implants [23]. Additionally, a number of xenogenic bone 
void fillers are currently used clinically, such as NuOss™ (Ace Surgical) and Bio-Oss® 
(Geistlich), which are both derived from bovine bone tissue. 
To date, most research incorporating naturally derived decellularised cartilage ECM for 
endochondral ossification has focused on the use of articular cartilage [24,25], a tissue that 
is known to be highly stable during adult life [26]. Conversely, when considering fracture 
repair it is likely that a source of cartilage which undergoes hypertrophy and ossification 
postnatally may offer significant advantages over articular cartilage  [27–29]. Postnatally, 
costal cartilage represents a plentiful source of cartilage that undergoes these changes. 
Costal cartilage is a hyaline cartilage tissue associated with the ribs and contains a region 
of hypertrophic chondrocytes [30], thus replicating the developmental bone forming 
cartilage and the postnatal fracture callus. Interestingly, despite costal cartilage 
undergoing slow bone formation physiologically in the rib environment, if transplanted 
subcutaneously it undergoes rapid endochondral remodelling [31]. 
Herein, we hypothesise that an optimised decellularisation of costal cartilage will result in 
non-immunogenic scaffolds that retain the native structure and desirable biological 
components required to control endochondral ossification.  
2. Materials and methods 
2.1. Costal cartilage harvest 
Fresh porcine costal cartilage was obtained from Large-White/Landrace crossbred pigs 
ranging from 40 to 70 Kgs (being terminated from unrelated studies at Northwick Park 
Institute for Medical Research; NPIMR, London, UK; approximately 8 ribs were harvested 
from each pig; n=5). Lateral thoracic incisions were made and the soft tissue excised and 
cleared to expose the costal regions of the rib cage.  Costal cartilage directly adjacent to 








































































































































































































removed using a sterile scalpel and the harvested costal cartilage placed in sterile plastic 
bags and stored immediately at -20°C. 
2.2. Development of decellularisation methodology 
Frozen costal cartilage samples were defrosted at room temperature. The cartilage tissue 
was dissected into discs measuring 10 mm in diameter and 1 mm in height, with a volume 
of 78.5 mm3. These discs were allotted into three groups each containing five discs.  These 
groups were subjected to three independent decellularisation methodologies (detailed in 
Supplementary Table 1). All the methodologies were carried out under negative pressure 
at 2000 µmHg (267 Pa), using a negative pressure desiccator (Sigma-Aldrich, Dorset, UK).   
All decellularisation methods utilised 250 mL of solution per step. All methodologies also 
included a nuclease digestion step to eliminate nucleic acids. The DNAse/RNAse buffers 
contained 10 mM CaCl2 and 60 mM MgCl2, required for the activity of nucleases. This step 
was carried out at 37°C under agitation using an orbital shaker (ThermoFisher, Bedford, 
UK). All non-enzymatic steps were carried out at 4-8ºC.  
Vac-OS methodology adapted from Greco and colleagues [32] utilised a freeze/thaw cycle 
to initiate cell disruption, followed by the use of hyper- and hypotonic steps in order to 
facilitate cell lysis. Washing with wash buffer containing Tween-20 (Sigma-Aldrich, Dorset, 
UK) was incorporated between each step to aid the removal fragmented cellular 
components. 
Vac-STx methodology adapted from Lange and colleagues [33] utilised a freeze/thaw cycle 
to initiate cell disruption, followed by a combination of sodium deoxycholate (SDC) (Sigma-
Aldrich, Dorset, UK) and Triton-X100 (Sigma-Aldrich, Dorset, UK) in order to facilitate cell 
lysis and the removal of cellular components, respectively. 
Vac-SDS methodology utilised sodium dodecyl sulphate (SDS), a zwitterionic detergent 
that solubilises cell membranes and dissociates DNA from proteins along with hyper- and 








































































































































































































All samples processed through each of the decellularisation methodologies were either 
preserved in PBS for DNA and GAG (n=3) analysis or fixed in 10% neutral buffered 
formalin-saline (NBF) for histological analysis (n=3). 
2.3. Assessment of cellular content removal 
2.3.1. Histological analysis 
Histological examination was used to assess cellular clearance and gross tissue 
morphology. Briefly, samples from each of the methodologies, along with a control 
sample, were fixed in 10% NBF for 24 hours at room temperature. The samples were 
processed for paraffin wax embedding using routine histological techniques. Subsequently, 
5 µM thickness paraffin sections were cut using a rotary microtome (ThermoFisher, 
Bedford, UK). The sections were mounted onto poly-lysine coated histology slides 
(ThermoFisher, Bedford, UK) and stained with haematoxylin and eosin according to routine 
procedures.  Additional sections were stained with 4′, 6-diamidino-2-fenylindool (DAPI) 
and visualised using inverted Axio fluorescence imager (Zeiss, UK). Nuclei were quantified 
using ImageJ (NIH). Based on histological examination the Vac-SDS was eliminated at this 
stage from further analysis. 
2.3.2. DNA quantification.  
To assess the quantity of DNA present, cartilage samples were cryomilled using a 
SPEXSamplePrep 6775 freezer mill (SPEX, London, UK) into a homogenous paste.  25 mg of 
the resultant paste was transferred to DNase/RNase free microcentrifuge tubes.  The total 
DNA of the samples was isolated using the GenElute mammalian genomic DNA miniprep 
kit (Sigma-Aldrich, Dorset, UK) in accordance with the manufacturer’s instructions and 
eluted in 50 µL nuclease-free water. The eluted DNA was quantified using the NanoDrop 
ND1000 spectrophotometer by absorbance (ThermoFisher, Bedford, UK) and normalised 
to the wet mass of each sample. Based on DNA and GAG quantification the Vac-STX 
condition was eliminated from further analysis and the Vac-OS methodology selected as 









































































































































































































2.3.3. Protein extraction and Western blotting for alpha-Gal content. 
Western blot analysis was utilised to determine the presence of the Alpha-Gal epitope. 
Briefly, Control cartilage, muscle and Vac-OS decellularised cartilage (dcECM) were 
cryomilled using a SPEXSamplePrep 6775 freezer mill (SPEX, London, UK) to form a paste. 
To further solubilise, 200 mg of the sample paste was combined with 1 mL of RIPA buffer 
(Sigma-Aldrich, Dorset, UK) and frozen at -80oC until analysed.  The total protein content of 
the lysate was quantified using a BCA protein assay kit (ThermoFisher, Bedford, UK) in 
accordance with the manufacturer's instructions. 10 µg of the protein was combined with 
2 x Laemmli sample buffer in a 1:1 ratio containing β-mercaptoethanol (Sigma-Aldrich, 
Dorset, UK) and size fractionated using SDS-PAGE, run on Mini-PROTEAN® TGX™ Precast 
Gels (Biorad, Herts, UK) followed by electrotransfer using the Trans-Blot® Turbo™ Mini 
PVDF Transfer Packs (Biorad, Herts, UK). The transferred proteins were stained using 1% 
Ponceau S (Sigma-Aldrich, Dorset, UK) for 1 hour. The blots were then blocked using 3% 
filtered bovine serum albumin (Sigma-Aldrich, Poole, UK), and incubated overnight at 4°C 
with an antibody against Alpha-Gal (EnzoLifeSciences, Exeter, UK) at 1:500 dilution. A 
secondary anti-mouse HRP conjugated antibody (VectorLabs, Cambs, UK) was then added 
to the blot at the concentration of 1:1000 and incubated for 1 hour at room temperature.  
Detected proteins were visualised using Clarity™ Western ECL Blotting Substrate (Biorad, 
Herts, UK) and images were obtained using ChemiDocXRS+ (Biorad, Herts, UK). 
2.4. Analysis of matrix components 
2.4.1. Sulphate glycosaminoglycan (sGAG) Quantification. 
The sGAG content in both control cartilage samples and decellularised samples were 
measured using the Blyscan s-GAG assay kit (Biocolor, Ireland). Briefly, each sample was 
cryomilled using a SPEXSamplePrep 6775 freezer mill (SPEX, London, UK) and 50mg of the 
sample was placed in 1.0 mL papain digestion buffer containing 400 mg sodium acetate, 
200 mg EDTA disodium salt, 40 mg cysteine HCL and 0.1mg papain for 12 hours at 65°C 
with occasional mixing. The digests were centrifuged at 13,000 rpm for 10 minutes.  50 µL 
of each digest supernatant was mixed with 1.0 mL Blyscan dye reagent.  The samples were 








































































































































































































centrifugation at 13,000 rpm for 10 minutes to obtain a pellet containing insoluble sGAG-
dye complex.  0.5 mL of dissociation reagent was added to each tube and centrifuged at 
13,000 rpm for 5 minutes.  A standard curve was generated with 50 µL serial dilutions 
ranging from 0.0-5.0µg/mL of chondroitin sulphate in distilled water.  The standards and 
samples were mixed with 1.0 mL Blyscan dye reagent and 200 µL of each transferred into 
clear flat bottom 96-micro well plates in triplicate. The absorbance was measured using a 
Tecan Infinite M200pro microtiter plate reader (Tecan, Männedorf, Switzerland) at 656 
nm.  Absolute sGAG content in µg/mL was determined and samples normalised to the wet 
mass of each sample. 
2.4.2. Differential scanning calorimetry (DSC).  
DSC was used to measure collagen denaturation temperatures as an indicator of the 
structural integrity of the matrix. Control native cartilage samples were compared to 
dcECM samples. Briefly, 10 mg of each sample was placed into 40 µL aluminium crucibles. 
The calorimetric experiments were performed using Mettler Toledo DSC-1 calorimeter 
(Mettler Toledo, Greenfield, UK). All experiments were performed between 25°C and 95°C 
at a heating rate of 3°C/min. The readings were normalised to an empty reference 
crucible. 
2.4.3. Multiphoton imaging   
Second harmonic generation and fluorescence-lifetime imaging microscopy (FLIM) were 
used to measure changes in the collagen biochemical environment as a measure of matrix 
integrity. Native costal cartilage and dcECM were placed in PBS in preparation for imaging. 
Laser scanning microscopy with multiphoton excitation was carried out using a Zeiss LSM 
510 microscope (Zeiss, Oberkochen, Germany) with a 10x 0.3 N.A water-dipping objective 
and the 80 MHz pulsed output of a Chameleon (Coherent, Santa Clara, USA) Ti:sapphire 
laser. Second harmonic generation and autofluorescence were observed using 920 nm and 
720 nm illumination wavelengths respectively. In both imaging modalities, a 650 nm 
dichroic filter separated the two-photon excitation from the shorter wavelength emission, 
collected with a 460(±25) nm band-pass filter before detection by a high-speed hybrid 








































































































































































































were recorded by a commercial time-correlated single photon counting SPC-830 
electronics module (Becker & Hickl, Berlin, Germany) in a desktop computer. Fluorescence 
lifetimes were extracted from the measured time-resolved emission data by least-squares 
fitting of a monoexponential decay in SPCImage (Becker & Hickl, Berlin, Germany). 
2.5. In vitro biocompatibility of dcECM 
2.5.1 Human articular chondrocyte isolation.  
Human cartilage was harvested from the articular surfaces of the knee and hip from 
patients undergoing joint replacement surgeries.  Articular chondrocytes were extracted 
from cartilage using a methodology that was adapted from previous studies [34–37].  
Briefly, two grams of cartilage were finely minced and placed into a collagenase type IV 
(consisting of 4400 enzyme activity units) digestion buffer containing growth medium (GM) 
consisting of high-glucose Dulbecco’s Modified medium supplemented with 10% foetal 
bovine serum (FBS) (Invitrogen, Paisley, UK), 1 mM sodium pyruvate (Invitrogen, Paisley, 
UK) and antibiotic-antimycotic solution (100 units/mL penicillin, 100 μg/mL streptomycin 
and 0.25 μg/mL amphotericin B; Invitrogen, Paisley, UK) for 16 hours. The digest was 
passed through a 70µM cell strainer and centrifuged at 1300 rpm for 10 minutes. The 
resultant chondrocyte pellet was resuspended in growth medium and expanded in 
monolayer until passage 2 and cryopreserved. Informed consent was obtained 
preoperatively from each patient in accordance with the approval from the Ethical 
Committee of the Royal National Orthopaedic Hospital in compliance with the United 
Kingdom Human Tissues Act 2004. 
2.5.2. Chondrocyte seeding and micromass culture.  
Human primary articular chondrocytes were thawed, sub-cultured and upon confluence at 
passage 3, were seeded in micromass cultures directly onto the plastic surface or onto 
dcECM at a density of 5x105 per 100 µL of growth media into the centre of a well. 
Micromass culture is extensively used in chondrogenic differentiation protocols as it 
effectively mimics cell aggregation and allows an intra-aggregate environment to be 
acquired that is permissive for differentiation[38]. These events mimic those that occur in 








































































































































































































sections using a biopsy punch (ThermoFisher, Bedford, UK). 5x105 chondrocytes in 10 µL of 
growth media were seeded onto the surface of the dcECM, whereby the low seeding 
volume aided localisation of the cells on the surface of the dcECM until attachment. Cells 
were seeded in micromasses and onto the dcECM surface at the same density. The cells 
were left for 3 hours to attach, following which 2 mL of growth media supplemented with 
5% FBS was added, micromasses were cultured in these conditions for a period of 7 days 
(n=3 per group). The media in each well was replaced daily with fresh growth media. 
2.5.3. Human periosteal stem cells (hPDSCs).  
hPDSCs were isolated as previously described [37]  (obtained from Prof Frank Luyten, KU 
Leuven, Belgium).  Subsequently, hPDSCs from a pool of six different donors were 
expanded to passage 5.  All experiments described herein were performed in pooled 
hPDSCs at passage 6. 
2.5.4. hPDSC seeding and micromass culture. 
Micromass cultures (MM) were seeded as previously described. Briefly, hPDSCs (passage 
6) were seeded at a cell density of 1x106 per 100 µL of growth media into 96-well plates. 
Cells were seeded at this density onto the dcECM as previously described and allowed to 
attach for 3 hours before being treated with various chondrogenic media.  The cells 
seeded in micromasses and on the dcECM were segregated into 3 media condition groups 
(n=3 per group).  The control group was treated with low glucose DMEM (Invitrogen, 
Paisley, UK) supplemented with 2% FBS, (Invitrogen, Paisley, UK) and antibiotic-
antimycotic solution (100 units/mL penicillin, 100 μg/mL streptomycin and 0.25 μg/mL 
amphotericin B; Invitrogen, Paisley, UK).  The second group consisted of basal 
chondrogenic group or C(-) group consisting of low-glucose DMEM (Gibco, UK) 
supplemented with 100µM ascorbate-2-phosphate (Sigma-Aldrich, Dorset, UK), 100nM 
dexamethasone (Sigma-Aldrich, Dorset, UK), 40 mg/mL proline (Sigma-Aldrich, Dorset, UK), 
and ITS+premix universal culture supplement (BD Biosciences, Bedford, MA) and  10 µM of 
Y27632 (Axon Medchem, Groningen, Netherlands ). The final group consisted of 
chondrogenic or C(+) group containing basal chondrogenic media supplemented with 10 








































































































































































































2.5.5. Total RNA extraction and quantitative reverse transcription–Polymerase Chain 
Reaction (qRT-PCR) analysis.  
Total RNA was extracted using the Trizol method. Briefly, seeded dcECM constructs were 
washed with PBS, placed in 350 μL of Trizol (Invitrogen, Paisley, UK) and homogenised. 
Total RNA was isolated from each of the micromasses and dcECM using the Direct-zol RNA 
MiniPrep (Cambridge Biosciences, Cambs, UK) according to the manufacturers’ 
instructions.  Total RNA isolated was quantified using the Nanodrop 1000 
spectrophotometer (ThermoFisher, Bedford, UK). Complementary DNA (cDNA) was 
synthesised by reverse transcription of 200ng of total RNA using the high capacity cDNA 
reverse transcription kit (Applied Biosciences, ThermoFisher, Bedford, UK). To detect 
messenger RNA (mRNA) transcripts, primers (exon spanning, designed using Primer3 Plus, 
NCBI) were premixed with iTaq universal SYBR green supermix (Biorad, Herts, UK) and 10 
μL aliquots were applied to Hard-Shell® 96-Well PCR Plates (Biorad, Herts, UK). Thermal 
cycling conditions were as follows: 10 min at 95°C, with 40 cycles of 15 seconds at 95°C, 30 
s at 60°C, and 20s at 72°C, on a Bio-Rad CFX1000 Real-Time System (Biorad, Herts, UK). 
Target gene quantification was achieved using the 2-ΔΔCT method described by Livak et al 
[39] relative to hPRT1 as the housekeeper gene.  Primer sequences are listed in 
Supplementary Table 2. 
2.6. In vivo biocompatibility 
6-week old BALB/C mice were purchased from Charles River, UK and were housed in 
polypropylene cages at 21°C (±2°C), subjected to 12-hour light and dark cycles, and were 
acclimatised for one week prior to use.  Mice were fed a standard RM1 maintenance diet 
ad libitum (Rat and Mouse No.1; Special Diet Services).  All procedures were conducted in 
accordance with the United Kingdom Animal Scientific Procedures Act, 1986 and were 
approved by the Ethics and Welfare Committee of the Comparative Biology Unit, Royal 
Free and University College London Medical School, London.   
Mice were anesthetised (3–5% isoflurane, O2 flow rate of 1.0 mL/min) and two 8 mm 
dorsal incisions created per mouse.  The subcutaneous pockets on each mouse were filled 








































































































































































































1mm thick). The incisions were then sutured with Vicryl Rapide sutures (Ethicon, UK). After 
2 and 8 weeks of implantation, mice were sacrificed by CO2 inhalation.  The dorsal skin was 
carefully resected and implants retrieved.  The dcECM and native cartilage tissue were 
fixed in 10% neutral buffered formalin (pH 7.4) (VWR, UK) for 24 hours at room 
temperature. 
The 10% NBF fixed tissues ((n=4) dcECM; (n=4) native costal cartilage), 2 and 8 weeks 
respectively) were dehydrated in graded alcohol, embedded in paraffin, and sectioned at 
5 μm.  Immunohistochemical analysis of CD68 (Pan-macrophage marker; Abcam, 
Cambridge, UK), CD86 (M1 macrophage marker; Abcam, Cambridge, UK), and CD163 (M2 
macrophage marker; Abcam, Cambridge, UK) was performed following deparaffinization 
and rehydration of the tissue sections.  All sections were blocked in 2.5% horse serum 
(VectorLabs, Cambs, UK) and 3% H2O2 (Sigma-Aldrich, Dorset, UK). For CD68 and CD163 
detection, antigen retrieval was performed by incubation with Tris-EDTA buffer (10 mM 
Tris base, 1 mM EDTA solution, 0.05% Tween 20, pH 9.0) at 60°C overnight. Antigen 
retrieval for CD86 was performed by incubation with proteinase K (Proteinase K ready to 
use solution (Dako, UK)) for 2 minutes at room temperature. Sections were then incubated 
with primary anti-CD68 (1:500 rabbit polyclonal anti-mouse; VectorLabs, Cambs, UK), anti-
CD86 (1:500 mouse monoclonal anti-mouse; VectorLabs, Cambs, UK) and anti-CD163 
(1:500 rabbit polyclonal anti-mouse; VectorLabs, Cambs, UK) at 4°C overnight. 
Subsequently, CD86 and CD163 sections were incubated with HRP-conjugated anti-rabbit 
secondary antibody solution (VectorLabs, Cambs, UK), CD86 sections were incubated with 
HRP-conjugated anti-mouse secondary antibody solution (VectorLabs, Cambs, UK) for 1 
hour at room temperature. All targets were visualised by incubation with the substrate 
3,3′-diaminobenzidine (VectorLabs, Cambs, UK) for 1 minute.  Tissue sections were 
counterstained with Haematoxylin solution (Sigma-Aldrich, Dorset, UK) and visualised 
using the Zeiss Apotome.2 microscope under bright field settings (Zeiss, UK). 
2.7. Statistical analysis 
Data are expressed as the mean ± standard deviation (SD). Statistical significance was 








































































































































































































corrections applied and Student’s t-test with Welch’s posthoc corrections applied to 
compare between independent groups. Statistical significance is indicated on all graphs as 
follows: *p<0.05, **p<0.01, ***p<0.001 (n=3).  All statistical analysis was performed using 
GraphPad Prism version 6.0f for windows (GraphPad Prism Software, La Jolla California 
USA, www.graphpad.com). 
3. Results 
3.1. An optimised Vac-OS decellularised methodology results in the effective removal of 
cellular components. 
Light microscopy of H&E stained sections revealed that all methodologies resulted in some 
level of cellular clearance, with the Vac-OS and Vac-STx methodologies resulting in the 
greatest clearance (Fig 1A). This was further validated through nuclear staining with DAPI 
and subsequent quantification (Fig 1B). The Vac-SDS based methodology resulted in an 
89.5% (p<0.001) reduction in DAPI positive nuclei. The Vac-STx and Vac-OS methodologies 
were the most effective at clearing cellular and nuclear content from the cartilage samples 
as evidenced by a 100% (p<0.001) reduction in visible DAPI positive nuclei.  These two 
methodologies were therefore chosen for further characterisation and assessment. 
3.2. Vac-OS decellularisation results in superior sGAG retention and the efficient removal 
of the Alpha-Gal epitope. 
To validate the effective removal of cellular and nuclear content from the decellularised 
cartilage samples the DNA content of the tissue was analysed.  Total DNA content in Vac-
OS and Vac-STx decellularised samples were quantified in 78.5 mm3 (small) and 785 mm3 
(large) sized cartilage pieces, normalised to tissue wet weight and compared to the control 
native costal cartilage samples. There was no significant difference in DNA content 
between the small and large samples with either of the methodologies employed.  
Furthermore, DNA content in both Vac-OS and Vac-STx decellularisation methodologies 
(Fig 2; A&B) resulted in values falling below the clinically acceptable level of 50 ng/mg 








































































































































































































Despite the similarity in DNA content, distinct differences in sGAG retention (Fig 2; C&D) 
between the two methodologies and tissue volumes were observed. Tissue subjected to 
the Vac-OS methodology retained 85.79% (p<0.05) and 28.2% (p<0.001) sGAG for the large 
and small volumes, respectively; when compared to control cartilage tissue. Tissue 
subjected to the Vac-STx methodology, however, retained 57.64% (p<0.001) and 16.64% 
(p<0.001) for the large and small volumes, respectively. The results indicated that the Vac-
OS decellularisation methodology resulted in 28.15% (p<0.001) greater sGAG content 
retention compared to the Vac-STx methodology, when considering the larger volumes. 
This difference in sGAG retention was not observed between the two methodologies in the 
smaller tissue volume.  The Vac-OS decellularisation with larger tissue volumes was thus 
selected as the optimal methodology for costal cartilage and subjected to further analysis. 
The presence of alpha-Gal epitope, which is an abundant immunogenic component found 
on the cell surface of all non-primate species, was investigated [40]. Immunoblotting 
revealed a 56 kDa band, indicating alpha-Gal was present (Fig 2F; protein loading is shown 
in Fig 2E) in control muscle (lanes 1&2) and cartilage tissues (lanes 3&4), but was absent in 
the Vac-OS decellularised sample groups (lanes 5, 6, & 7).  
3.3. Matrix analysis indicates minimal disruption to the Vac-OS decellularised matrix. 
The matrix integrity of the Vac-OS decellularised samples was further assessed using 
thermal analysis to determine collagen denaturation temperatures, thus indicating 
collagen structural integrity.  These analyses were compared to the collagen denaturation 
temperatures obtained from native costal cartilage. This analysis indicated that there were 
no significant changes in the denaturation temperatures between the dcECM compared to 
native costal cartilage (Fig 3; A&B). This was further reflected in the matrix analysis carried 
out using multiphoton imaging techniques (Fig 3C-F). The highly noncentrosymmetric 
structure of fibrillar collagen gives rise to intense second harmonic generation when 
exposed to a high-intensity coherent light source [41]. This allows collagen structures to be 
imaged using laser scanning microscopy by observing light emitted from a sample at half 
the wavelength of the incident illumination. Collagen also possesses intrinsic fluorescence 








































































































































































































fluorophores [42]. Changes in the nanoscale local environment of these fluorophores are 
reflected by alterations in their fluorescence lifetime[43], the average time taken for 
emission to occur following excitation. Combining second harmonic and fluorescence 
lifetime imaging would allow the assessment of morphological changes within the 
extracellular matrix.  Remarkably, there was no significant difference between control and 
dcECM fluorescence lifetimes, suggesting minimal changes in the biochemical environment 
of the extracellular matrix following the Vac-OS decellularisation process compared to 
native cartilage (Fig 3F). In contrast, dcECM treated with collagenase demonstrated both 
reduced collagen denaturation temperatures and altered fluorescence lifetimes 
(Supplementary Fig 1). 
3.4. dcECM promotes chondrogenic differentiation of skeletal cells. 
To assess the capacity for cell attachment and promotion of a chondrogenic phenotype, 
de-differentiated human chondrocytes were seeded onto the dcECM (Fig 4).  Cell 
attachment onto the dcECM was illustrated by nuclear and cytoskeletal staining (Fig 4A), 
revealing that the attached cells migrated into the vacant chondrocyte lacunae. 
Furthermore, the establishment of a chondrogenic phenotype of seeded cells was 
confirmed by a significant 4-fold (p<0.01) increase in COL2A1 mRNA expression associated 
with cartilage matrix maintenance (Fig 4B). There was no significant difference in 
chondrogenic commitment marker SOX9 mRNA expression. To further examine the 
chondrogenic potential of the scaffolds, hPDSCs were seeded onto the dcECM and in 
micromasses, and examined for cell attachment (Fig 4C).  Cells within micromasses under 
control conditions appeared more elongated with fibroblast-like morphology, whilst those 
under C(+) conditions (containing TGF-β) displayed a more distinct rounded morphology 
indicative of chondrocytic phenotype after 7 days (Fig 4C).  To understand these 
observations and assess the interaction of the cells with the dcECM, hPDSCs seeded onto 
the dcECM and in micromasses were either stimulated with C(+)  or cultured under control 
conditions.  Chondrogenic gene marker expression after 7 days was assessed (Fig 4D).  
There was no significant change in any of the markers between cells seeded onto the 
dcECM and micromasses under control conditions. In contrast, under chondrogenic (C+) 








































































































































































































with a 3-, 5- and 3.6-fold (p<0.001, p<0.05, p<0.01), respectively compared to 
micromasses.  Furthermore, under chondrogenic C(+) conditions an 8- and 4-fold (p<0.01, 
p<0.01) upregulation in cartilage matrix specific markers ACAN and COL2A1 were 
observed. This was also accompanied by the potent upregulation of markers associated 
with chondrocyte hypertrophy with a 2- and 2.9 fold (p<0.05, p<0.05) increase in RUNX2 
and COL10A1 expression. The importance of the TGF-β1 driven C(+) condition for 
enhanced chondrogenesis and hypertrophy was demonstrated through the comparison of 
the seeded dcECM in C(+) to the seeded dcECM in control conditions. These data 
demonstrated a potent 3.4-, 3.6-, 18- and 2896-fold (p<0.01, p<0.01, p<0.01, p<0.001) 
upregulation in SOX9, SOX6, ACAN and COL2A1, respectively. Enhanced hypertrophy was 
confirmed by a 24-fold (p<0.001) upregulation in COL10A1 mRNA expression.  There was 
no significant change in any of the markers investigated in hPDSCs subjected to the C(-) 
culture conditions (that contained no TGF-β1),  in both micromass and dcECM cultures 
(Data not shown). 
3.5. Subcutaneously implanted dcECM elicits a predominantly M2 macrophage-mediated 
anti-inflammatory regenerative response. 
The dcECM was subcutaneously implanted into mice to assess the in vivo immune 
response in comparison to native costal cartilage tissue. Explanted samples were subjected 
to immunohistochemical (IHC) analysis for CD68 (Pan-macrophage marker), CD86 (M1-
macrophage marker) and CD163 (M2-macrophage marker) (Fig 5). Qualitative analysis of 
the stained sections revealed a similar CD68 positive immune cell presence within the 
fibrous tissue (FT) that bordered the implant, between both the native costal cartilage and 
the dcECM at 2 and 8 weeks. After a period of 8 weeks, however, there was an observed 
decrease in CD86 staining with the dcECM compared to the 2-week samples and native 
samples at this time point. Another distinct observation was the presence of CD163 
positive cells in the FT surrounding the dcECM both at the 2 and 8-week time points, 
compared to the native cartilage samples. This indicates a predominantly M2 macrophage-










































































































































































































There is currently an unmet clinical need for treatment approaches aimed at enhancing 
the fracture repair process for the treatment of fracture non-union. Herein, we describe 
the production of innovative hyaline cartilage scaffolds that retain the native ECM 
architecture and biological cues required to enhance skeletal cell differentiation.  
Effective decellularisation is reliant on the efficient elimination of immunogenic cellular 
components without interfering with the intended biological function of the resultant ECM 
scaffold.  This is particularly challenging with dense avascular tissues such as cartilage 
[44,45].  Recent studies applying vacuum-assisted decellularisation demonstrate increased 
decellularisation efficiency, especially with respect to complex organs that include dense 
tissues i.e. trachea and larynx [33,46].  The enhanced cellular clearance reduces the need 
for harsh physical or enzymatic treatments that may contribute to the loss of bioactive 
molecules from the ECM [33,46]. Similarly, osmotic shock has also been applied towards 
the efficient decellularisation of dense tissues with minimal ECM disruption[32,47] and 
was therefore combined with vacuum assistance to formulate the optimised Vac-OS 
methodology (Supplementary Table 1) used in this study. This methodology (Vac-OS) was 
also compared to previously used vacuum-assisted decellularisation (Vac-STx) that 
incorporated the detergents triton-x and sodium deoxycholate (SDC) [33]. Interestingly, 
despite the Vac-OS methodology lacking any ionic surfactants, the resultant scaffolds 
(dcECM) exhibited DNA content falling below levels that are known to be immunogenic in 
vivo [22]. In addition, enhanced sGAG retention was also observed with the Vac-OS 
methodology compared to both the Vac-STx and other published methodologies aimed at 
decellularising cartilaginous tissues [25,48]. 
sGAGs are present in various tissue types but are especially abundant in cartilaginous ECM, 
serving as both structural and functional components [26,49]. Besides their role in ECM 
homoeostasis [50], sGAGs have also been associated with their ability to drive 
chondrogenesis [51–53] and in the regulation of endochondral ossification [54]. Therefore, 
the maintenance of sGAG content is essential when developing a scaffold with a capacity 








































































































































































































allowed for the retention of up to 85% of the native sGAG content, which was observed 
specifically when tissue volume was upscaled by a factor of ten. The synergy between 
osmotic shock and vacuum assisted decellularisation was further highlighted by the 
enhanced retention of GAGs compared to the Vac-STx methodology. These findings 
suggest that the disruptive and proteolytic nature of ionic surfactants such as SDC[55] may 
be key facilitators of sGAG loss. Indeed, several other studies that employ the use of ionic 
surfactants and enzymes report similar findings [25,56,57].  
A key promoter of xenogeneic transplant rejection is the alpha-gal epitope, which is a 
cellular component found on all non-primate species and is known to elicit an acute 
inflammatory response in humans. [40]. Therefore, the reduction or elimination of this key 
antigen is essential for clinical translation [58–60]. Moreover, the presence of residual 
alpha-gal in commercially available xenografts has been shown to have negative clinical 
outcomes[61–63].  Encouragingly, the high level of alpha-gal present within native costal 
cartilage tissue was successfully reduced below detectable levels by the Vac-OS 
methodology.  
The ECM structure and 3D spatial arrangement of macromolecules both play a vital role in 
cellular adhesion, stem cell fate determination and in vivo tissue remodelling [64–66]. 
Maintenance of ECM structure should, therefore, be thoroughly considered during the 
development decellularisation methodologies. Most studies utilise standard histological 
techniques for the assessment of decellularised cartilaginous matrices, which only allow 
for the gross examination of matrix architecture [67,68]. Therefore, DSC was used to gain 
an enhanced understanding of the dcECM collagen integrity.   Interestingly, it has 
previously been reported that alterations in articular cartilage matrix integrity between 
healthy and osteoarthritic cartilage are reflected by variations in the collagen denaturation 
temperatures [69]. Therefore, the unaffected collagen denaturation temperatures 
between the native costal cartilage and the dcECM are reflective of the preservation of 
collagen ultrastructure post Vac-OS. Unfortunately, DSC is destructive and only provides a 
global view of matrix integrity, hence, FLIM was utilised as an alternative approach to 
monitor subtle changes in the ECM. It is widely accepted that site-specific changes in 








































































































































































































lifetimes of collagen auto-fluorescence [70]. In agreement with the DSC data, the FLIM 
analysis did not uncover any significant changes in collagen fluorescence lifetimes between 
the dcECM scaffolds and native costal cartilage. To our knowledge, this is the first report of 
FLIM being used to assess matrix integrity of decellularised ECM that could be widely 
applied in the nondestructive monitoring of tissue during the optimisation of 
decellularisation approaches.  
The successful clinical application of a tissue-engineered implant depends on its ability to 
attract and direct tissue-specific remodelling via its interaction with surrounding stem cell 
populations. Chondrocytes are a cell type native to hyaline cartilage and are involved in 
cartilage homoeostasis [71], however, they are known to rapidly lose their chondrocytic 
phenotype following culture in monolayer[72,73]. Interestingly, dcECM promoted the re-
establishment of a chondrogenic phenotype from culture expanded (dedifferentiated) 
chondrocytes, indicated by a significant upregulation of COL2A1expression.  This is 
potentially the result of the retention of sufficient sGAG content [49,74,75], an 
undisrupted ECM ultrastructure [76] and, although not investigated in this study, the 
presence of remnant growth factors such as TGF- [77], BMP2 [78], FGF-2 and FGF-18 [79].  
To further elucidate the chondrogenic capacity of dcECM, human periosteal stem cells 
(hPDSCs), which are essential for fracture repair [80–83], were investigated. When 
combined with the dcECM, hPDSCs significantly upregulated expression of the 
chondrocyte genes SOX9, SOX5, SOX6, COL2A1 and ACAN.  Interestingly, there was also a 
upregulation of COL10A1, RUNX2 and VEGFA, which are representative of chondrocyte 
hypertrophy [10,84,85]. Moreover, these events were detected following a period of just 7 
days.  Interestingly, the upregulation of chondrogenic and hypertrophic markers were only 
observed in seeded dcECM constructs, cultured in conditions containing TGF-β. This may 
be due to the ability of the retained GAGs to sequester exogenously added TGF-β, thus 
enhancing its chondrogenic potential [49,74,75].  
For the successful translation of tissue engineered constructs, they must elicit a favourable 
immune response upon implantation, whilst avoiding a pro-inflammatory response that 
could hinder the natural tissue repair cascade and/or result in tissue rejection. The 








































































































































































































implantation into immunocompetent mice. The dcECM demonstrated a predominantly M2 
biased response at 2 and 8 weeks, which is indicative of favourable long-term outcomes 
and tissue-specific remodelling [86]. This was in contrast to the native costal cartilage 
comparator that demonstrated a predominantly M1 mediated response, which is linked to 
the initiation of inflammation. This further supports the in vitro analysis that demonstrates 
the effective removal of immunogenic factors.  
The validity of using decellularised cartilage tissue as an endochondral substrate has been 
previously demonstrated by Gawlitta and colleagues [25] and Cunniffe and colleagues [27]. 
The choice of articular cartilage-derived scaffolds used in the study by Gawlitta is, 
however, questionable as articular cartilage is highly stable during adult life, except in 
disease conditions [87]. Indeed, factors such as chondromodulin 1 (ChM-I) have been 
implicated in the stability of articular cartilage by inhibiting angiogenesis [88], a process 
essential for endochondral fracture healing [2]. Furthermore, Cunniffe and colleagues 
demonstrated that only scaffolds derived from in vitro hypertrophic chondrocyte ECM 
promoted vascularisation, induced mineralization and promoted bone formation[27]. Their 
use of cell-derived cartilage scaffolds, however, will pose major challenges when 
considering the fabrication of constructs of a clinically viable size [27,89,90]. Work carried 
out by Scotti and colleagues attempted to overcome this limitation by upscaling the size of 
previously developed cell constructs [89] through the addition of a collagen type I scaffold 
[91]. Although the approach yielded constructs capable of undergoing endochondral 
ossification, the efficacy of the process still remains highly reliant on an abundant stem cell 
population and extended culture periods.  
5. Conclusion 
To our knowledge, this is the first study that details the applicability of decellularised 
xenogeneic costal cartilage for the fabrication of fracture callus mimetic scaffolds. Herein, 
a vacuum-assisted decellularisation methodology that allows for the rapid fabrication of 
non-immunogenic costal cartilage-derived scaffolds capable of directing cell fate is 
described.  The presented data indicate that the dcECM is capable of enhancing 








































































































































































































implantation in an immunocompetent host.  The aforementioned characteristics 
demonstrate that the produced constructs may act as biomimetic implants that replicate 
several features of the fracture callus. It is hypothesised that these constructs could 
enhance bone repair in cases of atrophic nonunion fracture, where the failure of callus 
formation is a defining event. 
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Figure 1: Vac-OS and Vac-STx based decellularisation methodologies result in complete 
clearance of intact cellular nuclei. (A) Representative histological (n=3) analysis of cellular 
clearance from hyaline cartilage indicates removal of cellular content (scale bar = 50 µm). 
(B) Image-based quantification of intact nuclei using ImageJ presented as mean ±SD (n=3 
**p<0.01, ***p<0.001). Statistical analysis performed using a one-way ANOVA using 










































































































































































































Figure 2: Upscaling scaffold size does not impede DNA clearance but does enhance GAG 








































































































































































































based methodologies.  Data presented as mean ng/mg wet mass of tissue ±SD.  Both 
scaffold volume DNA contents fell below the threshold of 50 ng/mg for the Vac-STx and 
Vac-OS treated samples. Percentage sGAG content per mg wet mass tissue ±SD, subjected 
to (C) Vac-STx (n=3) and (D) Vac-STx (n=5) methodologies, normalised to native cartilage 
sGAG content. Statistical analysis was performed using a one-way ANOVA, using 
Bonferonni’s posthoc correction. Vac-OS decellularisation eliminates highly immunogenic 
alpha-Gal epitopes. (E) Representative images of Ponceau S staining of transferred 
proteins indicating the presence of protein bands in each lane. (F) Representative 
Immunoblot image illustrating the presence of the Alpha-Gal epitope at 56 kDa in both the 
control muscle (lanes 1&2), control cartilage samples (lanes 3 &4) and absence in Vac-OS 










































































































































































































Figure 3: Vac-OS decellularised ECM matrix integrity is maintained post decellularisation. 
Example differential scanning calorimetry thermal analysis curves and quantification of 
average denaturation temperatures comparing control cartilage vs dcECM samples, (*Peak 
denaturation temperature). (C) Second harmonic generation (SHG) microscopy image. The 
dcECM (C2) retains its architecture with minimal changes observed in lacunae size. (D) 
Two-photon autofluorescence image at 720 nm excitation. (E) False coloured fluorescence 
lifetime imaging microscopy (FLIM) images indicative of the distribution of the 
fluorescence lifetimes of the samples. (F) ImageJ quantification of the ROI’s, measuring the 
average fluorescence lifetimes (n=3).  Representative quantification data are represented 










































































































































































































Figure 4: dcECM promotes cell attachment and upregulates chondrogenic gene 
expression of skeletal cell populations. (A) Structured illumination microscopy images of 








































































































































































































indicating cells residing within the lacunae. (B) Chondrogenic markers; SOX9 and COL2A1 
mRNA expression as measured by qPCR. Results are expressed as the mean fold change 
normalised to micromass (MM) culture conditions ± SD (n=3 **p<0.01).  Statistical analysis 
performed using a unpaired t-test with Welch's posthoc correction. (C) Representative 
fluorescence images of hPDSCs seeded in micromass and on the dcECM under control 
conditions [CTRL] and chondrogenic conditions [C(+)] containing TGF-β. Fluorescence 
images were obtained using structured illumination (scale bar = 50 µm). (D) Chondrogenic 
gene expression of hPDSCs seeded in MM and dcECM under control conditions (CTRL) and 
C(+) conditions.  SOX9, SOX5, SOX6, ACAN, COL2A1, VEGF-A, COL10A1 and RUNX2 mRNA 
expression were measured by qPCR. Results are expressed as the mean fold change 
normalised to micromass cultures in control (MM-CONTROL) conditions ± SD (n=3 *p<0.05, 
**p<0.01, ***p<0.001).  Statistical analysis was performed using one-way ANOVA 










































































































































































































Figure 5: dcECM implanted into immunocompetent mice results in a predominantly M2 
macrophage-mediated response. Representative brightfield images of subcutaneously 
implanted native and dcECM cartilaginous constructs (CT) and host cellular infiltrate (FT). 
IHC was performed to visualise CD68 (Pan-macrophage marker), CD86 (M1-macrophage 









































































































































































































Supplementary Table 1: Decellularisation methodologies, highlighting each step along 
with the length of time 
Vac-OS Vac-STx Vac-SDS 
Freeze/Thaw 
Length: 24 Hours 
Freeze/Thaw 
Length: 24 Hours 
Freeze/Thaw 
Length: 24 Hours 
Distilled Water 
Length: 6 Hours 
0.25% Triton X + 0.25% SOC
Length: 24 Hours 
1% SDS 
Length: 4 Hours 
Hypertonic Solution 
Length: 12 Hours 
HBSS 
Length: 24 Hours 
PBS 
Length: 12 Hours 
Wash Buffer 
Length: 12 Hours 
DNAse/RNAse
Length: 24 Hours 
Hypertonic Sol 
Length: 10 Hours 
Hypotonic Solution 
Length: 12 Hours 
HBSS 
Length: 24 Hours 
PBS 
Length: 12 Hours 
DNAse/RNAse 
Length: 24 Hours 
Sterilisation Hypotonic Sol 
Length: 10 Hours 
Wash Buffer 
Length: 12 Hours 
 DNAse/RNAse 
Length: 12 Hours 
PBS 
Length: 12 Hours 
 PBS 
Length: 24 Hours 










































































































































































































Supplementary Table 2: Primer sequences used in the study 
Gene ID NCBI accession 
number 
 Sequence 5'-3' 
COL2A1 NM_001844.4 Forward GGCTTCCATTTCAGCTATGG 
 Reverse AGCTGCTTCGTCCAGATAGG 
SOX9 NM_000346.3 Forward TGGAGACTTCTGAACGAGAGC 
 Reverse CGTTCTTCACCGACTTCCTC 
SOX5 NM_001261414.2 Forward TGCTTACTGACCCTGATTTACC 
 Reverse CACTCTCCTCTTCTTCCACTTTC 
SOX6 NM_001145811.1 Forward AACAACGGCAGCAAATGGAC 
 Reverse CATGTGACCCTGAACCTGGA 
VEGF-A NM_001025366.2 Forward AGTCCAACATCACCATGCAG 
 Reverse TTCCCTTTCCTCGAACTGATTT 
RUNX2 NM_001015051.3 Forward CGCATTCCTCATCCCAGTAT 
 Reverse GCCTGGGGTCTGTAATCTGA 
COL10A1 NM_000493.3 Forward ACGATACCAAATGCCCACAG 
 Reverse GTGGACCAGGAGTACCTTGC 
ACAN NM_001135.3 Forward TGTGGGACTGAAGTTCTTGG 
 Reverse AGCGAGTTGTCATGGTCTG 
HPRT1 NM_000194.2 Forward TGAGGATTTGGAAAGGGTGT 









































































































































































































Supplementary figure 1: Further disruption of the Vac-OS decellularised scaffold using 
collagenase results in significant collagen denaturation and fluorescence changes. (A-C) 
False coloured fluorescence lifetime imaging microscopy (FLIM) images indicative of the 
distribution of the fluorescence lifetimes within the samples. (D) Quantification of average 
denaturation temperatures comparing control cartilage vs dcECM vs collagenase treated 
Vac-OS samples. (E) ImageJ quantification of the ROI’s, measuring the average 
fluorescence lifetimes (n=3).  Representative quantification data is represented as mean ± 
SD.  Statistical analysis performed using a unpaired t-test with Welch's post-hoc correction. 
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